

Michael Kreuter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3751262/publications.pdf>

Version: 2024-02-01

93
papers

6,281
citations

101384

36
h-index

74018

75
g-index

97
all docs

97
docs citations

97
times ranked

6537
citing authors

#	ARTICLE	IF	CITATIONS
1	<scp>SARS</scp> â€CoVâ€2 receptor <scp>ACE</scp> 2 and <scp>TMPRSS</scp> 2 are primarily expressed in bronchial transient secretory cells. EMBO Journal, 2020, 39, e105114.	3.5	812
2	Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2022, 205, e18-e47.	2.5	780
3	Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2020, 202, e36-e69.	2.5	508
4	Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respiratory Medicine,the, 2020, 8, 147-157.	5.2	410
5	Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respiratory Medicine,the, 2021, 9, 476-486.	5.2	254
6	Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis. PLoS ONE, 2016, 11, e0151425.	1.1	223
7	Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 356-363.	2.5	193
8	Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respiratory Medicine,the, 2016, 4, 381-389.	5.2	189
9	Palliative care in interstitial lung disease: living well. Lancet Respiratory Medicine,the, 2017, 5, 968-980.	5.2	185
10	Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis. An International Modified Delphi Survey. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1036-1044.	2.5	174
11	Global incidence and prevalence of idiopathic pulmonary fibrosis. Respiratory Research, 2021, 22, 197.	1.4	170
12	Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. Respiratory Research, 2017, 18, 139.	1.4	135
13	Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respiratory Medicine,the, 2016, 4, 445-453.	5.2	108
14	Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial. BMC Pulmonary Medicine, 2017, 17, 122.	0.8	94
15	Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2). BMJ Open Respiratory Research, 2019, 6, e000422.	1.2	79
16	Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international caseâ€cohort study. European Respiratory Journal, 2017, 50, 1700936.	3.1	75
17	Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?. Lancet Respiratory Medicine,the, 2017, 5, 591-598.	5.2	71
18	Bleeding risk of transbronchial cryobiopsy compared to transbronchial forceps biopsy in interstitial lung disease â€a prospective, randomized, multicentre cross-over trial. Respiratory Research, 2019, 20, 140.	1.4	69

#	ARTICLE	IF	CITATIONS
19	Patients with IPF and lung cancer: diagnosis and management. <i>Lancet Respiratory Medicine</i> , 2018, 6, 86-88.	5.2	67
20	Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis. <i>Thorax</i> , 2017, 72, 148-153.	2.7	66
21	Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis. <i>Respiration</i> , 2018, 95, 301-309.	1.2	66
22	Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management. <i>Respiratory Research</i> , 2021, 22, 109.	1.4	65
23	Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone. <i>Respiration</i> , 2017, 93, 415-423.	1.2	63
24	Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2016, 47, 1776-1784.	3.1	61
25	Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives. <i>BioMed Research International</i> , 2015, 2015, 1-10.	0.9	60
26	Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 1146-1153.	2.5	60
27	Transcriptome profiling reveals the complexity of pirfenidone effects in idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2018, 52, 1800564.	3.1	54
28	Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views. <i>Respiration</i> , 2018, 96, 514-524.	1.2	54
29	The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicentre observational study. <i>European Respiratory Journal</i> , 2019, 53, 1801587.	3.1	50
30	Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial. <i>BMJ Open Respiratory Research</i> , 2018, 5, e000289.	1.2	48
31	Associations between comorbidities, their treatment and survival in patients with interstitial lung diseases – a claims data analysis. <i>Respiratory Research</i> , 2018, 19, 73.	1.4	47
32	Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases: Rationale, Aims, and Design of a Nationwide Prospective Registry – The EXCITING-ILD Registry. <i>BioMed Research International</i> , 2015, 2015, 1-9.	0.9	42
33	Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis. <i>Respiration</i> , 2018, 96, 314-322.	1.2	41
34	Visual vs Fully Automatic Histogram-Based Assessment of Idiopathic Pulmonary Fibrosis (IPF) Progression Using Sequential Multidetector Computed Tomography (MDCT). <i>PLoS ONE</i> , 2015, 10, e0130653.	1.1	40
35	Nintedanib in Idiopathic Pulmonary Fibrosis: Practical Management Recommendations for Potential Adverse Events. <i>Respiration</i> , 2019, 97, 173-184.	1.2	39
36	Emergency Ultrasound of the Chest. <i>Respiration</i> , 2014, 87, 89-97.	1.2	37

#	ARTICLE	IF	CITATIONS
37	Transbronchial Cryobiopsies for Diagnosing Interstitial Lung Disease: Real-Life Experience from a Tertiary Referral Center for Interstitial Lung Disease. <i>Respiration</i> , 2019, 97, 348-354.	1.2	37
38	Residual symptoms and lower lung function in patients recovering from SARS-CoV-2 infection. <i>European Respiratory Journal</i> , 2021, 57, 2003002.	3.1	37
39	Quality of life assessment in interstitial lung diseases: a comparison of the disease-specific K-BILD with the generic EQ-5D-5L. <i>Respiratory Research</i> , 2018, 19, 101.	1.4	36
40	Pirfenidone: an update on clinical trial data and insights from everyday practice. <i>European Respiratory Review</i> , 2014, 23, 111-117.	3.0	34
41	Photoaging smartphone app promoting poster campaign to reduce smoking prevalence in secondary schools: the Smokerface Randomized Trial: design and baseline characteristics. <i>BMJ Open</i> , 2016, 6, e014288.	0.8	34
42	The need for a holistic approach for SSc-ILD – achievements and ambiguity in a devastating disease. <i>Respiratory Research</i> , 2020, 21, 197.	1.4	33
43	What patients with pulmonary fibrosis and their partners think: a live, educative survey in the Netherlands and Germany. <i>ERJ Open Research</i> , 2017, 3, 00065-2016.	1.1	31
44	Comorbidities and survival in patients with chronic hypersensitivity pneumonitis. <i>Respiratory Research</i> , 2020, 21, 12.	1.4	29
45	Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials. <i>Respiratory Research</i> , 2020, 21, 36.	1.4	29
46	Recurrent somatic mutations are rare in patients with cryptic dyskeratosis congenita. <i>Leukemia</i> , 2018, 32, 1762-1767.	3.3	27
47	Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression. <i>American Journal of Hematology</i> , 2020, 95, 1158-1169.	2.0	25
48	Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study. <i>Respiratory Research</i> , 2021, 22, 268.	1.4	24
49	Antacid Medication and Antireflux Surgery in Patients with Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. <i>Annals of the American Thoracic Society</i> , 2022, 19, 833-844.	1.5	23
50	Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry: Table 1. <i>BMJ Open Respiratory Research</i> , 2014, 1, e000010.	1.2	22
51	Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Uncertainties and Controversies. <i>Respiration</i> , 2018, 96, 571-587.	1.2	21
52	Screening for <i>Helicobacter pylori</i> in Idiopathic Pulmonary Fibrosis Lung Biopsies. <i>Respiration</i> , 2016, 91, 3-8.	1.2	20
53	Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases. <i>European Respiratory Review</i> , 2018, 27, 180078.	3.0	20
54	Economic burden of incident interstitial lung disease (ILD) and the impact of comorbidity on costs of care. <i>Respiratory Medicine</i> , 2019, 152, 25-31.	1.3	20

#	ARTICLE	IF	CITATIONS
55	Optical coherence tomography detects structural abnormalities of the nasal mucosa in patients with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2016, 15, 216-222.	0.3	19
56	A Novel Lipid Biomarker Panel for the Detection of Heart Failure with Reduced Ejection Fraction. <i>Clinical Chemistry</i> , 2017, 63, 267-277.	1.5	19
57	S2K Guideline for Diagnosis of Idiopathic Pulmonary Fibrosis. <i>Respiration</i> , 2021, 100, 238-271.	1.2	19
58	Antifibrotic drugs as treatment of nonidiopathic pulmonary fibrosis interstitial pneumonias. <i>Current Opinion in Pulmonary Medicine</i> , 2017, 23, 418-425.	1.2	17
59	Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns. <i>European Respiratory Journal</i> , 2016, 48, 1524-1526.	3.1	16
60	C-proSP-B: A Possible Biomarker for Pulmonary Diseases?. <i>Respiration</i> , 2018, 96, 117-126.	1.2	15
61	Evolution and treatment of idiopathic pulmonary fibrosis. <i>Presse Medicale</i> , 2020, 49, 104025.	0.8	15
62	Pleuroparenchymal fibroelastosis in association with carcinomas. <i>Respirology</i> , 2016, 21, 191-194.	1.3	13
63	The threat in chronic lung diseases: acute exacerbations. <i>European Respiratory Review</i> , 2017, 26, 170075.	3.0	12
64	Profibrotic epithelial TGF- β 1 signaling involves NOX4-mitochondria cross talk and redox-mediated activation of the tyrosine kinase FYN. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 320, L356-L367.	1.3	12
65	Supportive and Palliative Care of Advanced Nonmalignant Lung Disease. <i>Respiration</i> , 2011, 82, 307-316.	1.2	11
66	Hospitalisation patterns of patients with interstitial lung disease in the light of comorbidities and medical treatment – a German claims data analysis. <i>Respiratory Research</i> , 2020, 21, 73.	1.4	10
67	The Diagnosis and Treatment of Pulmonary Fibrosis. <i>Deutsches A&#x0308;rztblatt International</i> , 2021, 118, .	0.6	10
68	Use of a Genomic Classifier in Patients with Interstitial Lung Disease: A Systematic Review. <i>Annals of the American Thoracic Society</i> , 2021, , .	1.5	10
69	The Ariane-IPF ERS Clinical Research Collaboration: seeking collaboration through launch of a federation of European registries on idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2019, 53, 1900539.	3.1	8
70	A Comparison of Existing Questionnaires for Identifying the Causes of Interstitial and Rare Lung Diseases. <i>Respiration</i> , 2020, 99, 119-124.	1.2	8
71	Epidemiology, healthcare utilization, and related costs among patients with IPF: results from a German claims database analysis. <i>Respiratory Research</i> , 2022, 23, 62.	1.4	7
72	Impact and Safety of Adjuvant Chemotherapy on Pulmonary Function in Early Stage Non-Small Cell Lung Cancer. <i>Respiration</i> , 2014, 87, 204-210.	1.2	6

#	ARTICLE	IF	CITATIONS
73	Anti-acid treatment in patients with IPF: interpret results from post-hoc, subgroup, and exploratory analyses with great caution – Authors' reply. <i>Lancet Respiratory Medicine</i> , 2016, 4, e48.	5.2	6
74	Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use. <i>Advances in Therapy</i> , 2022, 39, 1081-1095.	1.3	6
75	Research highlights from the 2018 ERS International Congress: interstitial lung diseases. <i>ERJ Open Research</i> , 2019, 5, 00215-2018.	1.1	5
76	Cost drivers in the pharmacological treatment of interstitial lung disease. <i>Respiratory Research</i> , 2021, 22, 218.	1.4	5
77	Management of idiopathic pulmonary fibrosis: selected case reports. <i>European Respiratory Review</i> , 2014, 23, 239-248.	3.0	4
78	The yin and yang of idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2017, 49, 1602316.	3.1	4
79	Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design. <i>Advances in Therapy</i> , 2019, 36, 3059-3070.	1.3	4
80	Prognostic Value of Oxygenated Hemoglobin Assessed during Acute Exacerbations of Chronic Pulmonary Disease. <i>Respiration</i> , 2021, 100, 387-394.	1.2	4
81	Interstitial lung diseases: quo vadis?. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1084-1087.	5.2	4
82	Gender Differences in Health Care Workers' Risk-Benefit Trade-Offs for COVID-19 Vaccination. <i>Respiration</i> , 2022, 101, 646-653.	1.2	4
83	Current and Future Therapies for Idiopathic Pulmonary Fibrosis. <i>Pulmonary Therapy</i> , 2015, 1, 1-18.	1.1	2
84	Gazing into the crystal ball: can treatment response be predicted in IPF?. <i>Lancet Respiratory Medicine</i> , 2018, 6, 570-572.	5.2	2
85	Reply to: Malnutrition in idiopathic pulmonary fibrosis: the great forgotten comorbidity!. <i>European Respiratory Journal</i> , 2019, 53, 1900615.	3.1	2
86	Suggestions for improving clinical utility of future guidelines for diagnosis and management of idiopathic pulmonary fibrosis: results of a Delphi survey. <i>European Respiratory Journal</i> , 2021, 57, 2004219.	3.1	2
87	A 65-year-old man with an endobronchial gossypiboma after lobectomy for abscessing pneumonia. <i>Respiratory Care</i> , 2010, 55, 933-6.	0.8	2
88	Diagnostic Yield of Transbronchial Lung Cryobiopsy Compared to Transbronchial Forceps Biopsy in Patients with Sarcoidosis in a Prospective, Randomized, Multicentre Cross-Over Trial. <i>Journal of Clinical Medicine</i> , 2021, 10, 5686.	1.0	2
89	Interstitial lung diseases: course report. <i>Breathe</i> , 2016, 12, 213-215.	0.6	1
90	Tobacco Use, Knowledge about Smoking-Associated Risks, and Cessation Programs among Dental Students in Germany – ToDent. <i>Respiration</i> , 2020, 99, 764-770.	1.2	1

#	ARTICLE	IF	CITATIONS
91	One-step closer to solve the mystery of predicting disease progression in systemic sclerosis associated interstitial lung disease?. Thorax, 2021, 76, 1170-1171.	2.7	0
92	IPF, comorbidities and management implications: Patient case 1. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2015, 32 Suppl 1, 24-5.	0.2	0
93	Editorial: Interstitial Lung Disease Around the World. Frontiers in Medicine, 2022, 9, 865334.	1.2	0